Are sophorolipids and their derivatives lethal against human pancreatic cancer cells?
These results suggest that sophorolipids and select derivatives may be effective in treating human pancreatic cancer. Furthermore select derivatives may use different mechanisms toward this end. The ability to chemoenzymatically modify sophorolipids can provide effective lead compounds toward the treatment of pancreatic cancer.
Our results suggest that soluble E-cadherin levels are not able to predict patients' prognosis and underline the importance of external validation in prognostic marker research. Molecular markers predicting disease progression after radical cystectomy to identify high-risk patients and improve therapy decisions are still needed.